...
机译:对未接受过HIV-1感染的患者施用洛匹那韦,阿扎那韦和依法韦仑治疗方案后抗逆转录病毒药物反应的非线性混合效应模型
Department of Pharmacology, The Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden;
Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden;
Department of Infectious Diseases, Sundsvall Hospital, Sundsvall, Sweden;
Department of Infectious Diseases, Malmö University Hospital, Malmö, Sweden;
Department of Infectious Diseases, Ullevål University Hospital, Oslo, Norway;
Department of Infectious Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden;
Department of Infectious Diseases, Malmö University Hospital, Malmö, Sweden;
Department of Pharmacology, The Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden;
Department of Infectious Diseases, The Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden;
Antiretroviral; HIV-RNA; Limit of quantification; NONMEM;
机译:含洛匹那韦,阿扎那韦和依非韦伦的方案对未经治疗的HIV-1感染患者的抗逆转录病毒药物反应的非线性混合效应建模。
机译:在未接受过HIV-1感染的初次治疗的NORTHIV试验中,治疗结果与依非韦伦,依他那韦或洛匹那韦的暴露量之间的关系
机译:开始依法韦伦,洛匹那韦-利托那韦或阿扎那韦-利托那韦加替诺福韦/依米他滨治疗的严重免疫抑制抗HIV-初治HIV-1感染患者的免疫重建:最终48周结果(Advanz-3试验)
机译:幼稚艾滋病毒感染患者的两种第一线推荐的抗逆转录病毒方案:efavirenz为基于Lopinavir-Ritonavir的HAART
机译:用于从人血浆中同时测定抗逆转录病毒药物阿扎那韦,达鲁那韦,依非韦伦,依曲韦林,洛匹那韦,拉格列韦,利托那韦的UPLC-MS / MS方法的验证。
机译:依非韦伦利托那韦增强的洛匹那韦和奈韦拉平为基础的抗逆转录病毒疗法对恶性疟原虫阴性艾滋病毒感染的马拉维成虫中鲁美替林的药代动力学和蒿甲醚-卢美他汀安全性的影响被抗逆转录病毒稳定
机译:PIN73为艾滋病毒-1感染初治患者进行了模拟,将Atazanavir / R与Darunavir / R,Lopinavir / R和Efavirenz相比,开始使用Atazanavir / R进行治疗的长期临床结果和医疗保健成本影响:意大利,西班牙,葡萄牙和英国的国家/地区结果